Glossary · Research

ELITE (Early versus Late Intervention Trial with Estradiol)

Also called: Early versus Late Intervention Trial with Estradiol.

Definition: ELITE was a randomized trial that tested whether oral estradiol's effect on atherosclerosis progression depended on time-since-menopause. It found that women starting estradiol within 6 years of menopause had slower carotid intima-media thickening than placebo, while women 10+ years post-menopause did not — strong support for the timing hypothesis.

Detailed definition

The Early versus Late Intervention Trial with Estradiol (ELITE) randomized 643 healthy postmenopausal women to oral 17β-estradiol 1 mg/day (with vaginal progesterone in women with a uterus) or placebo, stratified by time since menopause: early (<6 years post-menopause) or late (≥10 years). The primary outcome was rate of change in carotid intima-media thickness (CIMT) over a median 5 years. Results: in the early stratum, women on estradiol had significantly slower CIMT progression than placebo (a marker of slower atherosclerosis). In the late stratum, there was no significant difference. The finding directly supports the timing hypothesis — estrogen's vascular effect depends on the underlying vasculature's state, with early-postmenopausal endothelium responding favorably and later-postmenopausal endothelium less so.

Why it matters in menopause

ELITE's direct test of timing-stratified estradiol effects provides perhaps the cleanest randomized evidence for the timing hypothesis. The mechanistic implication: starting HRT for healthy postmenopausal women within roughly the first decade after menopause has favorable vascular effects that disappear or reverse with later initiation.

Sources

External references: Wikipedia.

← Back to full glossary